Given the pleiotropic effects of SGLT2 inhibitors, it remains difficult to fully exclude the possibility that their kidney protective effects are mediated, at least in part, through improved insulin resistance as a consequence of better glucose control. This evidence concerns the gene SLC5A2 and Insulin resistance.